Abstract
Natural derived or originated compounds still play a major role as drugs, and as lead structures for the development of synthetic molecules. About 50% of the drugs introduced to the market during the last 20 years are derived directly or indirectly from small biogenic molecules. In the future, natural products will continue to play a major role as active substances, model molecules for the discovery and validation of drug targets. A multidisciplinary approach to drug discovery involving the generation of truly novel molecular diversity from natural product sources, combined with total and combinatorial synthetic methodologies provides the best solution to increase the productivity in drug discovery and development. Screening for new drugs in plants implies the screening of extracts for the presence of novel compounds and an investigation of their biological activities. It is currently estimated that approximately 420 000 plant species exist in nature. For the purpose of lead discovery, or for the scientific validation of a traditional medicinal plant or a phytopharmaceutical, active principals in complex matrices need to be identified. Therefore, the interfacing of biological and chemical assessment becomes the critical issue. Drug discovery from plants can be guided by epidemiologic studies facilitated with computer assisted HPLC microfractionation and microplate technology. Epidemiologic studies have shown that high dietary flavonoid intake may be associated with decreased risk for cardiovascular disease. Chlamydia pneumoniae is a common human pathogen and epidemiological and clinical studies have shown a connection between chronic C. pneumoniae infection, atherosclerosis and the risk of myocardial infarction. We will present here the detection of natural compounds active against C. pneumoniae as an example.
Keywords: drug discovery, natural products, high troughput screening, chlamydia, flavonoids
Current Medicinal Chemistry
Title: Natural Products in the Process of Finding New Drug Candidates
Volume: 11 Issue: 11
Author(s): P. Vuorela, M. Leinonen, P. Saikku, P. Tammela, J.- P. Rauha, T. Wennberg and H. Vuorela
Affiliation:
Keywords: drug discovery, natural products, high troughput screening, chlamydia, flavonoids
Abstract: Natural derived or originated compounds still play a major role as drugs, and as lead structures for the development of synthetic molecules. About 50% of the drugs introduced to the market during the last 20 years are derived directly or indirectly from small biogenic molecules. In the future, natural products will continue to play a major role as active substances, model molecules for the discovery and validation of drug targets. A multidisciplinary approach to drug discovery involving the generation of truly novel molecular diversity from natural product sources, combined with total and combinatorial synthetic methodologies provides the best solution to increase the productivity in drug discovery and development. Screening for new drugs in plants implies the screening of extracts for the presence of novel compounds and an investigation of their biological activities. It is currently estimated that approximately 420 000 plant species exist in nature. For the purpose of lead discovery, or for the scientific validation of a traditional medicinal plant or a phytopharmaceutical, active principals in complex matrices need to be identified. Therefore, the interfacing of biological and chemical assessment becomes the critical issue. Drug discovery from plants can be guided by epidemiologic studies facilitated with computer assisted HPLC microfractionation and microplate technology. Epidemiologic studies have shown that high dietary flavonoid intake may be associated with decreased risk for cardiovascular disease. Chlamydia pneumoniae is a common human pathogen and epidemiological and clinical studies have shown a connection between chronic C. pneumoniae infection, atherosclerosis and the risk of myocardial infarction. We will present here the detection of natural compounds active against C. pneumoniae as an example.
Export Options
About this article
Cite this article as:
Vuorela P., Leinonen M., Saikku P., Tammela P., Rauha P. J.-, Wennberg T. and Vuorela H., Natural Products in the Process of Finding New Drug Candidates, Current Medicinal Chemistry 2004; 11 (11) . https://dx.doi.org/10.2174/0929867043365116
DOI https://dx.doi.org/10.2174/0929867043365116 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Adverse Drug Reactions in Critical Care Settings: A Systematic Review
Current Drug Safety Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants
Current Clinical Pharmacology The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study
Endocrine, Metabolic & Immune Disorders - Drug Targets The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design New Insights into Vitamin D and Autophagy in Inflammatory Bowel Diseases
Current Medicinal Chemistry Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial: Pain in Dementia: A Distressing Combination of Several Factors
Current Alzheimer Research Brain Drug Delivery System: An Overview
Current Drug Therapy Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Culture-Independent Bacterial Population Analysis – Clinical Implications for Respiratory and Other Infections
Current Respiratory Medicine Reviews Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Caffeic Acid, A Versatile Pharmacophore: An Overview
Mini-Reviews in Medicinal Chemistry